Stryker completed the sale of its U.S. spinal implants business to Viscogliosi Brothers as part of the newly formed company, VB Spine.
Edge Medical distributes orthopedic surgical products in the UK and Irish markets.
GetSet provides sterile packaged single-use surgical kits, including the GoPLF! Posterior Lateral and GoLIF! Lumbar Interbody Fusion systems.
Certain IP assets related to Sites Medical’s OsteoSync titanium pads will be used to develop next-gen PEEK interbody fusion devices.
The Nevro1 implant is an FDA 510(k)-cleared device intended to transfix the SI joint for immediate stability and long-term fusion.
Stryker divested the majority of its spinal implant business while Zimmer Biomet agreed to acquire foot-and-ankle player Paragon 28.
Paragon 28 has a suite of surgical offerings and product systems spanning all major foot and ankle segments, including fracture and trauma, deformity correction and joint replacement.
The U.S. implants business will be sold to Viscogliosi Brothers. Plans follow to sell the related international spine business.
Anika plans to focus on its core hyaluronic acid technology and advance its differentiated Regenerative Solutions portfolio.
Vertos Medical offers interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis.
The integration brings offerings for joint replacement, spine, trauma, sports medicine, robotics and more.
Stryker expanded its foot & ankle portfolio with the purchase of 4WEB’s Osteotomy Truss and Ankle Truss systems.
Vertos Medical has developed mild, a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis.
The acquisition includes OrthoGrid’s fluoroscopy-based Hip AI surgical assistance platform, as well as two additional FDA-cleared orthopedic applications.
Artelon is a specialist in soft tissue fixation products for foot and ankle and sports medicine procedures.
This technology has been shown to grow bone rapidly in vivo without inducing bone synthesis at ectopic sites by non-bone cells.
The company seeks to sell its Poly-gamma-glutamic Acid technology related to OA, plus various intellectual property and know-how assets.
Login
Register for a free account
As a guest member you get access to more articles and videos every month.